Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Anesthesia Type and HoLEP Outcomes: A Multi-Center Study

9 de maio de 2026 atualizado por: Murat Gulsen, Ondokuz Mayıs University

Does Anesthesia Type Affect HoLEP Outcomes? A Multi-Center, Real-World Comparative Study

  1. What is this study about, and why is it required?

    The goal of this observational study is to learn if anesthesia type (e.g., general anesthesia, spinal anesthesia) affects the safety and efficiency of HoLEP surgery. The main question it aims to answer is:

    - Is a particular type of anesthesia related to less or more bleeding during the surgery?

  2. What will be assessed to answer the main question of this study? (Outcome measure(s))

    2.1. Primary outcome measure of this study is:

    - Change in the hemoglobin level perioperatively.

    2.2. Secondary outcome measures are:

    • Requirement for the usage of any vasoactive medication due to low blood pressure
    • Time passed until discharge.
    • Time passed until the removal of the bladder drainage catheter.
    • Ratio of the unwanted events that require additional intervention other than medication, fluids, or blood transfusions (Complications, Clavien-Dindo Grade III or higher).
    • International symptom questionnaire score 3 months after surgery.
    • Quality of life (QoL) score 3 months after surgery.
    • Peak urinary current velocity (Qmax) and post-void residual volume measurement 3 months after surgery.
  3. Can anyone participate in this study?

Voluntary participants should meet the following criteria:

  • Being older than 18 years old.
  • Having bothersome lower urinary tract symptoms due to prostatic enlargement requiring surgical treatment.
  • Having no untreated or uncontrolled systemic disease, which refers to having an ASA (American Society of Anesthesiologists Physical Status Classification System) score III at most.

Visão geral do estudo

Descrição detalhada

Benign prostatic obstruction (BPO) is the leading cause of lower urinary tract symptoms (LUTS) among men older than 40 years.

Surgery is recommended under circumstances such as:

  • Bothersome LUTS resistant to medical treatment.
  • Acute kidney injury, bladder stone(s), resistant hematuria and urinary retention.
  • Preference of the patient.

Various surgical methods exist to treat BPO, but the most appropriate choice depends on the operator and the patient.

HoLEP is an abbreviation for holmium laser enucleation of prostate, which is one of the endoscopic laser enucleation techniques.

Both spinal and general anesthesia are applicable for HoLEP surgery. The type of anesthesia is determined by the anesthesiologist, independently of the operator's preference, taking into account several factors related to the patient, such as safety and comfort.

Controlled bleeding is one of the expected outcomes in HoLEP, and several factors determine the amount of bleeding. For HoLEP, the type of anesthesia may be one of them, as other studies have claimed. This multicenter, prospective observational study may further reveal the impact of anesthesia type on bleeding.

The amount of bleeding could be "less or more", determined according to the content below:

  • Amount of hemoglobin and hematocrit decreased, measured by laboratory examinations, preoperatively, during, and on the day after the surgery.
  • Vital changes such as hypotension, tachycardia, that require blood transfusion due to "more" bleeding during either the surgery or hospital stay after surgery.
  • Usually, a shorter duration of bladder irrigation to clean blood in the urine during hospital stay after the surgery is required for "less" bleeding.

Participants who are eligible and willing to provide informed consent will undergo HoLEP. Preoperative, perioperative, and postoperative data will be collected without disclosing the participant or any personal data relating to the participant.

Participants will be grouped into two groups based on anesthesia type: general or spinal.

To answer the main question of this study, a power analysis was conducted, concluding that at least 320 participants are required (intention-to-treat population).

All collected data will be recorded and analyzed according to the proper statistical methods. Results will be reported.

Tipo de estudo

Observacional

Inscrição (Estimado)

320

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Murat Gulsen, Assistant Professor
  • Número de telefone: +905062357421
  • E-mail: mglotr@gmail.com

Locais de estudo

      • Samsun, Turquia (Türkiye)
        • Ondokuz Mayis University, Faculty of Medicine, Department of Urology
        • Contato:
          • Murat Gulsen, Assistant Professor
          • Número de telefone: +905062357421
          • E-mail: mglotr@gmail.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra de Probabilidade

População do estudo

Male patients undergoing HoLEP for BPO.

Descrição

Inclusion Criteria:

  • 18 years or older men who have BPO requiring surgical treatment.
  • Participants who can give written informed consent.
  • Having no more than 3 points for the American Society of Anesthesiologists (ASA) physical status classification scale (ASA 1 to 3).

Exclusion Criteria:

  • Absolute contraindication for spinal or general anesthesia
  • History of previous surgery for prostate (e.g., surgery for prostate cancer, surgery for benign prostate obstruction)
  • Uncorrected bleeding disorder (INR > 1.5)
  • Participants who are not willing to give informed consent.
  • Participants who have a proven urinary tract infection at the time of the surgery.
  • Participants who are not able to be contacted for regular follow-ups.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
General Anesthesia
Participants undergoing HoLEP under general anesthesia (intubation or laryngeal mask airway)
Spinal Anesthesia
Participants undergoing HoLEP under spinal anesthesia

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Hemoglobin change
Prazo: First day after HoLEP is performed.
Difference between preoperative and postoperative hemoglobin levels (g/dL)
First day after HoLEP is performed.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
International Prostate Symptom with quality of life score (IPSS-QoL) at 3 months after surgery
Prazo: At 3 months after HoLEP

The severity of lower urinary tract symptoms and their impact on quality of life should be assessed using a validated questionnaire.

  • 0 to 35 points for IPSS
  • 0 to 6 points for QoL Scale variable.
At 3 months after HoLEP
Duration of hospitalization
Prazo: Postoperative second to seventh days after HoLEP.
Day(s) passed until discharge after HoLEP.
Postoperative second to seventh days after HoLEP.
Duration of catheterization
Prazo: From the time of HoLEP until the removal of the catheter.
Day(s) passed until the removal of the bladder drainage catheter after HoLEP.
From the time of HoLEP until the removal of the catheter.
Ratio of high grade complications
Prazo: From the time of HoLEP to 30 days after HoLEP.
Complications will be classified according to the Clavien-Dindo classification. Clavien-Dindo Grade III or higher is considered a high-grade complication.
From the time of HoLEP to 30 days after HoLEP.
Peak Urinary Flow (Qmax)
Prazo: At 3 months after HoLEP.
Peak urinary flow (mL/sec), at 3 months after HoLEP.
At 3 months after HoLEP.
Post-void residual (PVR)
Prazo: At 3 months after HoLEP
Post-void residual (PVR) volume (mL) measurement at 3 months after HoLEP
At 3 months after HoLEP
Enucleation Efficiency
Prazo: From the start of HoLEP to the end of HoLEP (Operative time).
Weight of the enucleated adenoma per operative minute (grams/min).
From the start of HoLEP to the end of HoLEP (Operative time).
Ratio of intraoperative vasoactive medication requirement
Prazo: During the anesthesia for HoLEP
Number of participants who required vasoactive medication during anesthesia for HoLEP due to low blood pressure, as a percentage of the total number of participants.
During the anesthesia for HoLEP

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Murat Gulsen, Ondokuz Mayıs University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

23 de abril de 2026

Conclusão Primária (Estimado)

1 de agosto de 2027

Conclusão do estudo (Estimado)

1 de setembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

5 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de maio de 2026

Primeira postagem (Real)

13 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de maio de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • MIUS.2026.002

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data (IPD) will not be shared due to privacy concerns and data protection regulations, including the Turkish Personal Data Protection Law (KVKK).

Only aggregated, de-identified results will be reported in publications and presentations.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever